New Promising Alternatives for Mitral Regurgitation

PASCAL transcatheter valve repair system for mitral regurgitation has shown feasibility and safety to treat patients with grade 3+ or 4+, regardless etiology. Regurgitation grade was significantly reduced, and this was accompanied by clinical improvement in functional class, exercise capacity and quality of life.

Infarto agudo de miocardio y lesiones de múltiples niveles

This study soon to be published in J Am Coll Cardiol Intv is just a 30-day report on the new transcatheter mitral valve repair system PASCAL (Edwards Lifesciences, Irvine, California), but it is a promising tool that increases our arsenal to treat the mitral valve.

Eligible patients should have mitral valve regurgitation grade 3+ or 4+ and be symptomatic, despite optimal medical treatment. Major adverse events were adjudicated by an independent committee and echocardiographic images assessed by a central laboratory. Primary safety end points were major events at 30 days.

Between 2017 and 2018, 62 patients were enrolled, mean age 76.5, more than half (51.6%) were in functional class III-IV. Etiology was 56% functional, 36% degenerative and 8% mixed.


Read also: DES with Bioresorbable Polymer vs. Bare Metal Stents in Primary PCI.


At 30 days, major event rate was 6.5% with 1.6% all-cause mortality and no stroke. 98% reached ≤2+ regurgitation grade and 86% ≤1+ grade (p=0.0001). As regards symptoms, 85% reached functional class I or II (p=0.0001).

6-minute walk test improved 36 meters (p=0.0018) and quality of life questionnaires improved, the Kansas City Cardiomyopathy Questionnaire improved 17 points (p<0.0001) and the score EQ-5D 10 points (p=0.0004).

Conclusion

The transcatheter mitral valve repair system PASCAL showed feasibility and safety to treat patients with mitral valve regurgitation 3+ to 4+, regardless etiology.

Clinical improvement was significant, as was functional class, exercise capacity and quality of life.

Original Title: Transcatheter Valve Repair for Patients With Mitral Regurgitation 30-Day Results of the CLASP Study.

Reference: D. Scott Lim et al. J Am Coll Cardiol Intv 2019, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....